首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1548852

數位生物標記市場規模、佔有率和成長分析：按類型、臨床實踐、最終用途、地區 - 行業預測，2024-2031 年

Digital Biomarkers Market Size, Share, Growth Analysis, By Type, By Clinical Practice, By End-Use, By Region - Industry Forecast 2024-2031

出版日期: 2024年08月30日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球數位生物標記市場規模約24.3億美元，從2023年的29.6億美元成長到2031年，預測期間（2024-2031年）複合年成長率為21.9%，預計將達到144.4億美元。

由於健康相關行動應用程式、連網型數位設備、智慧型手機使用量的增加以及新型穿戴式設備的採用，數位生物標記市場預計將顯著成長。這些進步正在提高患者和醫生對心血管健康的了解，特別是透過檢測預示心臟病早期階段的心律不整。這種日益成長的興趣正在加速數位生物標記市場的擴張。這種成長得到了推動數位生物標記研究的投資和資金籌措增加的進一步支持。醫療技術公司也利用數位生物標記技術來對抗 COVID-19 大流行，為市場擴張做出貢獻。例如，Medopad 正在與全球合作夥伴合作，根據呼吸指標檢驗數位生物標記，以識別高風險的 COVID-19 患者，以及流行病如何對市場產生積極影響。此外，數位生物標記物超越了傳統的智慧型手錶和活動追蹤器。領先的製藥公司正在與創新的數位健康新興企業合作，以加強數位生物標記解決方案的採用和開發，預計這將進一步推動市場成長。由於 COVID-19 大流行帶來的挑戰，各國政府也對基於數位生物標記的治療表現出了興趣。儘管有潛在的好處，但資料隱私、可靠性、檢驗問題和缺乏開放原始碼資料等挑戰可能會阻礙市場成長。然而，日益激烈的競爭和這些技術的廣泛採用預計將在預測期內解決這些障礙。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

ActiGraph LLC（US）
AliveCor Inc.（US）
Koneksa（US）
Altoida Inc.（US）
Amgen Inc.（US）
Biogen Inc.（US）
Empatica Inc.（US）
IXICO plc（UK）
Adherium Limited（New Zealand）
Neurotrack Technologies, Inc.（US）
Aural Analytics（US）
Huma（UK）
Sonde Health, Inc.（US）
Clario（US）
Imagene AI（Israel）
Brainomix（UK）
Kinsa Inc.（US）
Solve.Care（Estonia）
HIVE Blockchain Technologies Ltd.（Canada）
Encrypgen（US）
Sana Benefits（US）
Healthereum（US）
Patientory（US）

簡介目錄

Product Code: SQMIG35G2218

Global Digital Biomarkers Market size was valued at around USD 2.43 billion in 2022 and is expected to rise from USD 2.96 billion in 2023 to reach a value of USD 14.44 Billion by 2031, at a CAGR of 21.9 % over the forecast period (2024-2031).

The market for digital biomarkers is expected to experience significant growth, driven by the rapid adoption of health-related mobile applications, connected digital devices, increased smartphone usage, and the introduction of new wearables. These advancements are enhancing patients' and doctors' understanding of cardiovascular health, particularly by detecting arrhythmias that can signal early stages of heart disease. This surge in interest is accelerating the expansion of the digital biomarkers market. The growth is further supported by increased investments and funding aimed at advancing research into digital biomarkers. Health technology companies have also leveraged their digital biomarker technologies to address the COVID-19 pandemic, contributing to market expansion. For example, Medopad is working with global partners to validate digital biomarkers for respiratory indicators and identify high-risk COVID-19 patients, illustrating how the pandemic is positively impacting the market. Moreover, digital biomarkers extend beyond traditional smartwatches and activity trackers. Major pharmaceutical companies are collaborating with innovative digital health startups to enhance the adoption and development of digital biomarker solutions, which is anticipated to further drive market growth. Governments are also showing interest in digital biomarker-based treatments due to the challenges posed by the COVID-19 pandemic. Despite the potential advantages, there are challenges such as data privacy, reliability, validation issues, and a shortage of open-source data that could hinder market growth. However, increased competition and broader adoption of these technologies are expected to address these obstacles during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Digital Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Biomarkers Market Segmental Analysis

The Biomarker Market is segmented based on type, clinical practice, therapeutic area, end users and region. Based on type, the market is segmented into Wearable, Mobile based Applications, Sensors, and others. Based on clinical practice, Diagnostic digital biomarkers, Monitoring digital biomarkers, Predictive and Prognostic digital biomarkers, Others. Based on therapeutic area, the market is segmented into Cardiovascular and metabolic disorders (CVMD), Respiratory disorders, Psychiatric disorders, Sleep & Movement Disease, Neurological disorders, Musculoskeletal disorders, Others (Diabetes, Pain Management). Based on end -users, the market is segmented into healthcare companies, Healthcare Providers, Payers, Others (Patient, caregivers). Based on region, North America, U.S., Canada, Mexico, Europe,UK, Spain, Italy, France, Denmark and others.

Drivers of the Global Digital Biomarkers Market

The increasing prevalence of chronic conditions like diabetes, cardiovascular diseases, and cancer is fueling the demand for digital biomarkers. These technologies play a crucial role in the early detection and effective management of such diseases. Digital biomarkers offer valuable insights that aid in identifying health issues at an earlier stage, which is essential for improving patient outcomes and managing chronic diseases more efficiently.

Restraints in the Global Digital Biomarkers Market

The absence of well-defined regulatory guidelines for digital biomarkers is impeding market growth by creating uncertainty for both investors and manufacturers. This lack of clarity makes it challenging for stakeholders to navigate the regulatory landscape, which can deter investment and slow the development of new technologies. The uncertainty surrounding regulatory requirements for digital biomarkers also affects the market's progress. Without clear guidelines, companies face difficulties in ensuring compliance and bringing new products to market, which in turn hampers the overall expansion of the industry.

Market Trends of the Global Digital Biomarkers Market

Wearables and mobile health apps are gaining widespread adoption among both consumers and healthcare providers due to their ability to facilitate continuous and remote patient monitoring. This growing trend is significantly contributing to the expansion of the digital biomarkers market. These devices generate vast quantities of data, which is instrumental in the development of digital biomarkers. As more people use wearables and health apps, the volume of data available for creating and refining digital biomarkers increases, further fueling market growth.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors of The Market
Degree Of Competition
Top Investment Pockets
Market Attractive Index
Ecosystem Mapping
Technology Analysis
Cost Analysis
Market Trend Analysis
Competition Analysis
Supply chain analysis
Investment Analysis
Application-Specific Analysis
Patent analysis
Trade analysis
Case study analysis

Digital Biomarkers Market by Type

Wearable
Mobile based Applications
Sensors
Others

Digital Biomarkers Market by Clinical Practice

Diagnostic digital biomarkers
Monitoring digital biomarkers
Predictive and Prognostic digital biomarkers
Others

Digital Biomarkers Market by Therapeutic Area

Cardiovascular and metabolic disorders (CVMD)
Respiratory disorders
Psychiatric disorders
Sleep & Movement Disease
Neurological disorders
Musculoskeletal disorders
Others
- Diabetes
- Pain Management

Digital Biomarkers Market by End-Use

Healthcare companies
Healthcare Providers
Payers
Others
- Patient
- Caregivers

Digital Biomarkers Market by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

ActiGraph LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AliveCor Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Koneksa (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altoida Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Empatica Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IXICO plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adherium Limited (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurotrack Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aural Analytics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Huma (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sonde Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clario (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imagene AI (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brainomix (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kinsa Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Solve.Care (Estonia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HIVE Blockchain Technologies Ltd. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Encrypgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sana Benefits (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Healthereum (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patientory (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments